Searching. Please wait…
1582
37
170
29108
4409
2600
347
389
Abstract: In the present study, we aimed to report our experience with rituximab (RTX) in the treatment of patients with ILD associated with AD (AD-ILD) at a single center. For this purpose, clinical characteristics, radiological findings, and pulmonary function tests (PFTs) of RTX-treated AD-ILD-patients seen from May 2016 until March 2020 at a referral center for individuals with ILD were retrospectively reviewed. Additionally, an updated literature review was conducted. A total of 26 patients (mean age 58.3 ± 11.1 years at ILD diagnosis) was included. The most common ADs related to ILD were systemic sclerosis, idiopathic inflammatory myositis (including anti-synthetase syndrome) and rheumatoid arthritis. Non-specific interstitial pneumonia (n = 12) and usual interstitial pneumonia (n = 11) were the predominant radiological patterns. The sustained improvement in PFTs was observed from the start of RTX, with a statistically significant increase in DLCO from basal to one year after RTX (mean + 4.2%, p = 0.024). Overall, there were no differences when comparing PFT outcome according to the radiological pattern or the specific type of AD. In conclusion, RTX constitutes a good therapeutic option to preserve lung function in patients with AD-ILD, regardless of the radiological pattern or the underlying AD.
Fuente: Journal of Clinical Medicine, 2020, 9(10), 3070
Publisher: MDPI
Publication date: 23/09/2020
No. of pages: 19
Publication type: Article
DOI: 10.3390/jcm9103070
ISSN: 2077-0383
Publication Url: https://doi.org/10.3390/jcm9103070
Consult in UCrea Read publication
ATIENZA-MATEO, BELÉN
REMUZGO-MARTÍNEZ, SARA
PRIETO-PEÑA, DIANA
MORA CUESTA, VICTOR MANUEL
DAVID ITURBE FERNANDEZ
FRANCISCO JAVIER LLORCA DIAZ
SÁNCHEZ-BILBAO, LARA
CORRALES, ALFONSO
BLANCO RODRÍGUEZ, GERARDO
JOSE JAVIER GOMEZ ROMAN
JOSE MANUEL CIFRIAN MARTINEZ
MIGUEL ANGEL GONZALEZ-GAY MANTECON
Back